Gene essentiality for tumour growth influences neoantigen‐directed immunoediting

Hyoeun Bang(Korea Advanced Institute of Science and Technology), Kwoneel Kim(Kyung Hee University), Seok Bo Shim(Kyung Hee University), Se‐Hoon Lee(Samsung Medical Center), Jae Soon Park(Korea Advanced Institute of Science and Technology), Jinhyeon An(Korea Advanced Institute of Science and Technology), Jeong Yeon Kim(Korea Advanced Institute of Science and Technology), Jung Kyoon Choi(Korea Advanced Institute of Science and Technology), Changhwan Sung(Ulsan College), Dae‐Yeon Cho(Medipost (South Korea))
Clinical and Translational Medicine
January 1, 2022
10.1002/ctm2.714
Cited by 0

Related Papers

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2024|233
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
|Journal of Clinical Oncology|2023|224
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
|Journal of Clinical Oncology|2024|131